Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Takeda Pharmaceutical Company Limited (4502.T)
Tokyo, JP
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.80% | -0.77% | -5.46% | -5.63% | +19.24% | +7.77% | +29.82% | +18.00% | +41.66% | +10.67% | +124.49% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 5 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-1.7% Q1'26: +3.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+78.0% ★ Q1'26: +76.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+9.1% Q1'26: -0.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+12.0% Q1'26: +4.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.3% Q1'26: +0.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.2% ★ Q1'26: -1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.87× Q1'26: 5.80× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 15 Rev. Ana. 12 EPS Ana. |
Mar 2027 8 Rev. Ana. 6 EPS Ana. |
Mar 2028 14 Rev. Ana. 11 EPS Ana. |
Mar 2029 10 Rev. Ana. 7 EPS Ana. |
Mar 2030 5 Rev. Ana. 2 EPS Ana. |
Mar 2031 4 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.78T
est: 1.76T (+1.2%)
|
1.81T
est: 1.83T (-1.2%)
|
1.73T
est: 1.72T (+0.5%)
|
1.77T
est: 1.78T (-0.5%)
|
2.10T
est: 2.17T (-3.1%)
|
3.29T
est: 3.31T (-0.5%)
|
3.20T
est: 3.22T (-0.6%)
|
3.57T
est: 3.49T (+2.3%)
|
4.03T
est: 4.02T (+0.2%)
|
4.26T
est: 4.41T (-3.4%)
|
4.58T
est: 4.61T (-0.7%)
|
4.54T
4.46T – 4.58T
-1.6% YoY
|
4.60T
4.49T – 4.66T
+1.4% YoY
|
4.64T
4.37T – 4.88T
+0.9% YoY
|
4.75T
4.75T – 4.76T
+2.4% YoY
|
4.95T
4.75T – 5.11T
+4.2% YoY
|
5.14T
4.93T – 5.30T
+3.7% YoY
|
| EBITDA |
57.29B
est: 486.76B (-88.2%)
|
310.24B
est: 507.11B (-38.8%)
|
325.24B
est: 477.79B (-31.9%)
|
412.06B
est: 493.32B (-16.5%)
|
443.48B
est: 600.14B (-26.1%)
|
681.47B
est: 917.00B (-25.7%)
|
1.07T
est: 891.84B (+20.4%)
|
1.04T
est: 966.90B (+7.9%)
|
1.18T
est: 1.11T (+6.4%)
|
927.95B
est: 1.22T (-24.1%)
|
1.13T
est: 1.28T (-11.8%)
|
1.26T
1.23T – 1.27T
-1.6% YoY
|
1.27T
1.25T – 1.29T
+1.4% YoY
|
1.29T
1.21T – 1.35T
+0.9% YoY
|
1.32T
1.32T – 1.32T
+2.4% YoY
|
1.37T
1.32T – 1.42T
+4.2% YoY
|
1.42T
1.37T – 1.47T
+3.7% YoY
|
| EBIT |
-134.30B
est: 191.59B (-170.1%)
|
129.00B
est: 199.60B (-35.4%)
|
153.82B
est: 188.06B (-18.2%)
|
229.94B
est: 194.17B (+18.4%)
|
195.79B
est: 236.21B (-17.1%)
|
97.83B
est: 360.93B (-72.9%)
|
513.87B
est: 351.03B (+46.4%)
|
459.67B
est: 380.57B (+20.8%)
|
520.11B
est: 438.33B (+18.7%)
|
199.95B
est: 481.40B (-58.5%)
|
366.05B
est: 503.27B (-27.3%)
|
495.02B
486.02B – 500.11B
-1.6% YoY
|
501.76B
490.27B – 508.20B
+1.4% YoY
|
506.13B
476.65B – 532.11B
+0.9% YoY
|
518.44B
517.67B – 519.21B
+2.4% YoY
|
540.30B
518.33B – 557.69B
+4.2% YoY
|
560.52B
537.73B – 578.56B
+3.7% YoY
|
| Net Income |
-145.78B
est: 146.24B (-199.7%)
|
80.17B
est: 153.43B (-47.8%)
|
114.94B
est: 205.16B (-44.0%)
|
186.89B
est: 340.32B (-45.1%)
|
135.19B
est: 199.00B (-32.1%)
|
44.24B
est: -155.70B (+128.4%)
|
376.01B
est: 271.62B (+38.4%)
|
230.06B
est: 243.74B (-5.6%)
|
317.02B
est: 325.12B (-2.5%)
|
144.07B
est: 149.92B (-3.9%)
|
107.93B
est: 136.92B (-21.2%)
|
240.39B
197.56B – 283.23B
+75.6% YoY
|
222.99B
220.34B – 269.36B
-7.2% YoY
|
304.50B
211.53B – 441.81B
+36.6% YoY
|
348.35B
233.90B – 701.29B
+14.4% YoY
|
523.06B
495.41B – 544.94B
+50.2% YoY
|
380.46B
360.35B – 396.38B
-27.3% YoY
|
| SGA |
612.49B
est: 441.90B (+38.6%)
|
650.34B
est: 460.38B (+41.3%)
|
619.06B
est: 433.76B (+42.7%)
|
628.11B
est: 447.86B (+40.2%)
|
692.73B
est: 544.83B (+27.1%)
|
964.27B
est: 832.48B (+15.8%)
|
875.51B
est: 809.64B (+8.1%)
|
886.33B
est: 877.79B (+1.0%)
|
997.23B
est: 1.01T (-1.4%)
|
1.05T
est: 1.11T (-5.1%)
|
1.10T
est: 1.16T (-4.8%)
|
1.14T
1.12T – 1.15T
-1.6% YoY
|
1.16T
1.13T – 1.17T
+1.4% YoY
|
1.17T
1.10T – 1.23T
+0.9% YoY
|
1.20T
1.19T – 1.20T
+2.4% YoY
|
1.25T
1.20T – 1.29T
+4.2% YoY
|
1.29T
1.24T – 1.33T
+3.7% YoY
|
| EPS |
-92.94
est: 91.10 (-202.0%)
|
102.26
est: 95.58 (+7.0%)
|
147.15
est: 127.80 (+15.1%)
|
239.35
est: 211.99 (+12.9%)
|
69.57
est: 123.96 (-43.9%)
|
28.41
est: -96.99 (+129.3%)
|
240.72
est: 169.20 (+42.3%)
|
147.14
est: 151.83 (-3.1%)
|
204.29
est: 202.52 (+0.9%)
|
92.09
est: 95.61 (-3.7%)
|
68.36
est: 86.08 (-20.6%)
|
141.11
123.06 – 176.43
+63.9% YoY
|
152.52
137.26 – 167.79
+8.1% YoY
|
204.48
131.77 – 275.22
+34.1% YoY
|
294.58
145.70 – 436.85
+44.1% YoY
|
325.83
308.61 – 339.46
+10.6% YoY
|
237.00
224.47 – 246.91
-27.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-15 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-14 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christophe Weber | President, Chief Executive Officer & Representative Director | 830M | male |
| Andrew S. Plump | President of Research & Development and Representative Director | 574M | — |
| Milano Furuta | Chief Financial Officer & Director | 232M | male |
| Haruhiko Hirate | Member of Management Board | — | male |
| Iwaaki Taniguchi | Senior Vice President of Corporate Finance & Controlling Department | — | male |
| Michael Fox | Chief Operating Officer | — | — |
| Mwana Lugogo | Chief Ethics & Compliance Officer | — | female |
| Norimasa Takeda | Chief Accounting Officer & Corporate Controller | — | — |
| Salvatore Alesci | Member of Management Board and Head of R&D Global Science & Biomedical Policy | — | male |
| Seigo Izumo | Chair of Management Board | — | — |
| Christopher David O'Reilly | Global Head of Investor Relations & Global Finance | — | male |
| Gabriele Ricci | Chief Data & Technology Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4502.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
